BioSpace News Archive

Apnimed, Inc. announced the publication of the full, clinically-significant results from the MARIPOSA Phase 2b trial in the American Journal of Respiratory and Critical Care Medicine, a premier journal in pulmonary, critical care and sleep medicine.

TechMah CMF LLC, an innovative medical device company, is pleased to announce the FDA 510(k) approval of its cutting-edge medical device, the tmCMF Solution.

ValGenesis, Inc and Valspec, a global provider of system validation and lifecycle services, have partnered to extend a suite of sophisticated ValGenesis products for life sciences clients in the U.S.

AbbVie (NYSE: ABBV) will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17.

Anika Therapeutics, Inc. announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.

Planatome announced it has completed its spinout from Entrepix, Inc., and is now a fully separate entity.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced data from two late-breaking posters presented at this year’s 28th International Annual Congress of the World Muscle Society (WMS) which took place in Charleston, South Carolina, from October 3-7, 2023.

Eckert & Ziegler and PharmaLogic Holdings Corp. have signed a reservation agreement for the supply of the therapeutic radioisotope Actinium-225.

Shuttle Pharmaceuticals Holdings, Inc. announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, is announcing that it intends to effect a one-for-seven reverse share split of its common shares.